Laddar populära aktier...
Redeye returns with a more detailed take on the Q3 report.
Higher sales and gross margin in Q3 EBIT revised up 12.
Redeye sees a solid Q3 report with an improved cash burn, and we welcome the increased gross margin target.
Higher sales growth and gross margin in Q3 EBIT +32% (lower loss) vs ABGSCe Estimates likely to be revised up 5-10% on EBIT '24e Q3 results...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Redeye gives its preview on OssDsign’s Q3 2024 report, due on November 5.
Solid sales but slightly higher opex EBIT revised down by 4.
Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that push our base case somewhat down.
Redeye sees a quarter demonstrating continued strong sales growth and an OPEX that is in line with our forecast.
Slightly higher opex drives miss on EBIT EBIT (loss) -9% vs ABGSCe Estimates likley to be revised down 2-4% on EBIT '24e Q2 results OssDsig...
Redeye gives its preview on OssDsign’s Q2 2024 report, due on August 20.
- Q2'24 results due 20 August - 142% growth y-o-y for Catalyst, +9.
Redeye returns with a more in-depth take on the Q1 report.
- Solid start in Q1 - Higher sales commissions weigh down on EBIT in '25e-'26e - Fair value revised down to SEK 8-15 (9-16) First quarter wi...
Redeye is encouraged by the strong gross margin in Q1 but at first glance, nothing in the report prompts any significant reconsiderations to...
Sales in line with expectations EBIT (loss) 10% better Estimates likley to be revised up 3-5% on EBIT '24e Q1 results OssDsign reported a s...
Redeye gives its preview on OssDsign’s Q1 2024 report, due on May 14.
Q1'24 results due 14 May 207% growth y-o-y, but limited sequential growth EBIT revised up 2% for '24e-'26e due to FX Q1'24 expectations We ...
Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into the report.
Small miss on underlying PTP in Q4 Higher non-recurring items than expected Fair value range down to SEK 9-16 (9-17) Another quarter with s...
Redeye sees a Q4 with sales coming in according to our estimates, but we note that costs came in higher than expected (both in COGS and OPEX...
Redeye shares its preview of OssDsign’s Q4 2023e results, due on February 6.
Q4'23 results due 6 February Already pre-announced strong sales for Oct-Nov Fully focused US orthobiologics company as of New Year Q4'23 ex...
Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further peer-reviewed publication in the intended ...
Redeye is encouraged by the preliminary Q4 (Oct-Nov) sales, and we positively review the sales estimates for Catalyst for 2023e-2025e.
Positive sales update for Q4 Oct-Nov sales of 25.2m (ABGSCe Q4 SEK 24) Implied upside of 13% to our FY '23e sales estimates Trading update ...
Catalyst växte med 155% under Q3’23 OssDsigns nettoomsättning för det tredje kvartalet 2023 uppgick till 31,7 mkr, vilket motsvarar 81% i ti...
Redeye returns with more insights on the Q3 report, and we continue to feel confident in OssDsign’s capabilities in increasing Catalyst sale...
74% FX-adj. sales growth in Q3, mainly driven by Catalyst Balance sheet strengthened through directed share issue Fair value range raised to...
Redeye provides its initial comment on OssDsign’s Q3 report.
Redeye shares its preview of OssDsign’s Q3 2023e results, due November 21.
Redeye returns with a more in-depth take on the discontinuation of Cranial.
Strategiskifte OssDsign kommer nu att fokusera enbart på kommersialiseringen av OssDsign Catalyst i USA, som utgör mer än 70% av den globala...
Value accretive shift in strategy Directed share issue of SEK 150m Fair value range up to SEK 9-15 (from 6-15) Shift in strategy We believe...
Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to focus entirely on its Catalyst product.
• Focus on orthobiologics going forward • New financial targets and rights issue • Expected to be accretive to earnings already in 2024 Cran...
Redeye is enthusiastic by today’s news of the FDA expanding the approval for Catalyst to interbody cages in spinal fusion.
79% FX-adj. sales growth in Q2, mainly driven by Catalyst Opex stabilising Fine-tune fair value range to SEK 6-15 Catalyst overtakes Crania...
Redeye raises its base case following a case review of OssDsign and we positively reconsider its commercial prospects for Catalyst.
148% tillväxt i USA. OssDsigns nettoomsättning under Q2 uppgick till 24 mkr vilket motsvarar 92% tillväxt (79% i fasta valutakurser), 148% t...
Sales up 203% y-o-y, and 6% better than ABGSCe 1,000 patients treated signals 25% Catalyst q-o-q growth in Q2 We raise sales by 3-2% for '23...
USA-försäljning upp med 339% OssDsigns nettoomsättning för det första kvartalet uppgick till 21,5 SEKm, vilket motsvarar en omsättningstillv...
Redeye sees another quarter in which OssDsign rolls out Catalyst full steam ahead.
Rapportkommentar Omsättningen för Q4 blev 19,9 mkr (9,2), upp 117% (89% CER).
Sales 15% better, EBIT 0% vs. ABGSCe We cut '23-'24e sales by 5-6% Lowered fair value range to SEK 6-16 (8-21) Cranial PSI strength behind ...
Staffing shortages in Q4 likely hurt volumes We cut '22e-'24e sales by 5-20% We have a positive view on Catalyst potential Influenza spread...
Redeye is encouraged by the continuous positive news flow related to Catalyst, and we embrace the just-announced first patient report from t...
Redeye leaves a brief comment on OssDsign’s directed share issue rendering an upwards adjustment to our fair value range.
Rapportkommentar Omsättning för Q3 blev 17,5 mkr (8,9) upp 96% (71% CER).
Redeye is encouraged by the strong sales development, boosted by Catalyst contributing to c60% of US sales.
Better sales as US grew 144% on Catalyst success Underlying estimates relatively unchanged Fair value range of SEK 8-21 unchanged Recently l...
Redeye is encouraged by the strong Q2 sales figures, underpinning our expectations for a strong H2 2022.
Rapportkommentar OssDsign rapporterade en stark försäljningsökning drivet av USA-marknaden som nu stod för 56% av bolagets totala försäljnin...
Managed to beat ABGSCe by 18% in tough conditions We lift our ’22e-’24e sales estimates by 5-9% Fair value range unchanged at SEK 8-21 /shar...
Sales worse than feared, but isolated to Q1 conditions Clinical and commercial progress bodes well for mid-term Reiterate our fair value ran...
Rapportkommentar OssDsign släppte under gårdagen sin Q1-rapport.
Redeye regards OssDsign’s Q1 as a relative non-event quarter; elective surgeries took a major toll in the early months of Q1, but the lower-...
Softer Q1 on long lead-times dampening sales High surgical activity bodes well for rest of ‘22e Fair value range of SEK 8-21 /share unchang...
Rapportkommentar Q4 OssDsign släppte under förra veckan sin rapport för det fjärde kvartalet.
Redeye returns with a more detailed take on the Q4’21 report.
Redeye notes another quarter where OssDsign delivers record sales, which were more or less in line with our estimates, but with costs higher...
Q3-rapport i linje med våra förväntningar Försäljningen i kvartalet kom in på 8,9 mkr (6,5 i Q3'20), motsvarande en organisk tillväxt om 39%...
Redeye endorses OssDsign's advancement in its clinical study for Catalyst (TOP FUSION), as the first of 17 patients has been enrolled.
OssDsigns rapport för det andra kvartalet innehöll inga större överraskningar.
Redeye comments on OssDsign’s Q2 report and emphasizes that activities during and after the quarter continue to support our favorable view o...
Redeye endorses the latest news surrounding OssDsign’s continuing expansion of its commercial network.
Redeye endorses OssDsign’s agreement with the GPO giant Premier, which boosts our confidence in our sales estimates, lining up the company a...
